Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H7N4O5.Na |
| Molecular Weight | 286.1761 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-][N+](=O)C1=CC=C(O1)\C=C\C=N\N2CC(=O)[N-]C2=O
InChI
InChIKey=LNKQENVGMUHHIX-NGTWICJZSA-M
InChI=1S/C10H8N4O5.Na/c15-8-6-13(10(16)12-8)11-5-1-2-7-3-4-9(19-7)14(17)18;/h1-5H,6H2,(H,12,15,16);/q;+1/p-1/b2-1+,11-5+;
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H8N4O5 |
| Molecular Weight | 264.1943 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 2 |
| Optical Activity | NONE |
Furagin (Furazidine) is a nitrofuran derivative, acting as an antibacterial medicine with bacteriostatic action. It is active against both gram-positive (Staphylococcus epidermidis, Staphylococcus aureus, Staphylococcus faecalis) and gram-negative microorganisms (Enterobacteriaceae – Salmonella, Shygella, Proteus, Klebsiella, Escherichia, Enterobacter, etc.). It is used for the treatment of urinary tract, skin and soft tissues infections.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Furagin Approved UseFuragin (Furazidine) is indicated for the treatment of urinary tract infections. Topical furagin is used in the treatment of infections of the skin and soft tissues. |
|||
| Curative | Furagin Approved UseFuragin (Furazidine) is indicated for the treatment of urinary tract infections. Topical furagin is used in the treatment of infections of the skin and soft tissues. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Experimental studies on a new chemotherapeutic preparation furazidin]. | 1958 Jul |
|
| Pharmacokinetics of furagin, a new nitrofurantoin congener, on human volunteers. | 1979 Jun |
|
| Ciprofloxacin and furagin in acute cystitis: comparison of early immune and microbiological results. | 2008 Feb |
Sample Use Guides
Adults: 50-100 mg t.i.d., for 7-14 days.
0.5% or 1% solution for topical applications.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:26:45 GMT 2023
by
admin
on
Sat Dec 16 10:26:45 GMT 2023
|
| Record UNII |
PD0LSG5BP0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000177766
Created by
admin on Sat Dec 16 10:26:46 GMT 2023 , Edited by admin on Sat Dec 16 10:26:46 GMT 2023
|
PRIMARY | |||
|
119025833
Created by
admin on Sat Dec 16 10:26:46 GMT 2023 , Edited by admin on Sat Dec 16 10:26:46 GMT 2023
|
PRIMARY | |||
|
PD0LSG5BP0
Created by
admin on Sat Dec 16 10:26:46 GMT 2023 , Edited by admin on Sat Dec 16 10:26:46 GMT 2023
|
PRIMARY | |||
|
22060-47-5
Created by
admin on Sat Dec 16 10:26:46 GMT 2023 , Edited by admin on Sat Dec 16 10:26:46 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|